Zanubrutinib with BEAM before stem cell transplant for relapsed DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests adding zanubrutinib to standard high-dose chemotherapy (BEAM) before a stem cell transplant for people with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if this combination helps control the lymphoma better before the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with diffuse large B-cell lymphoma that came back or did not fully respond after at least two prior treatments.
- You are between 18 and 65 years old.
- You have good performance status (able to do daily activities, ECOG 0-2).
- Your blood counts and organ function (liver, kidneys, heart) must be within acceptable ranges, as checked by standard lab tests.
- You have not had an autologous stem cell transplant before.
- You do not have lymphoma in the brain or spinal cord, active serious infections, or other uncontrolled medical issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new treatment for people with a type of lymphoma (DLBCL) that has not gone away or has come back. It combines a study drug called pirtobrutinib with a common chemotherapy regimen (BEAM) before a stem cell transplant, and the goal is to see if this approach is safe and effective in helping patients get to transplant.
This trial tests adding selinexor to a standard chemotherapy regimen (BEAM) before a stem cell transplant for people with a certain type of large B-cell lymphoma that has MYC positive. It aims to see if this combination can improve outcomes.
This trial tests a combination of targeted drugs and chemotherapy for patients whose large B-cell lymphoma has returned or not improved after first treatment. The goal is to see if this mix works better than standard options.
This trial is testing a combination of targeted drugs, including zanubrutinib, for people newly diagnosed with a fast-growing lymphoma called DLBCL. It is designed for patients with certain risk factors that make their lymphoma more aggressive, and it aims to see if these drug combinations can work better than standard treatments.
This Phase 3 study compares two chemotherapy schedules (Chi-BEAM vs BEAM) given before an autologous stem cell transplant to treat newly diagnosed peripheral T-cell lymphoma that responded to first-line treatment. If you fit the lab and heart/lung requirements, it may offer access to a new treatment approach designed to improve outcomes.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.